Tumor-associated AAbs have shown promise in CTLA-4 and PD-1 monoclonal antibody therapies for melanoma and lung cancer, exemplified by the survival association of NY-ESO-1 AAb in these patients. This evidence concerns the gene PDCD1 and lung carcinoma.